3 active not recruiting, 2 completed, 1 terminated. 6 Phase 2, 1 Phase 1.
By phase and status
Follow Tobemstomig: new trials by email Literature Review of Tobemstomig trials Research Report on Tobemstomig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tiragolumab - Carcinoma, Hepatocellular Phase 1 / Phase 2 Terminated Hoffmann-La Roche 62 2023-12-05 2026-09-15 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer Tobemstomig, Pembrolizumab, Nab-Paclitaxel - Breast Cancer Phase 2 Active not recruiting Hoffmann-La Roche 83 2023-07-18 2026-09-10 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Tobemstomig, Tiragolumab, Pembrolizumab - Renal Cell Carcinoma Phase 2 Active not recruiting Hoffmann-La Roche 199 2023-04-21 2026-08-10 A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer Atezolizumab, Tobemstomig, Tiragolumab - Urothelial Cancer Phase 2 Active not recruiting Hoffmann-La Roche 204 2023-04-13 2026-10-26 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer Tobemstomig, Pembrolizumab, Paclitaxel - Non-small Cell Lung Cancer Phase 2 Completed Hoffmann-La Roche 182 2023-03-15 2026-07-20 A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus Lomvastomig, Tobemstomig, Nivolumab - Advanced or Metastatic Esophageal Squamous Cell Carcinoma Phase 2 Completed Hoffmann-La Roche 190 2021-06-25 2026-03-27
Conditions studied Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Esophageal Squamous Cell Carcinoma (1)
Sponsors Hoffmann-La Roche (6)
Countries Spain (6) · France (5) · Germany (5) · South Korea (5) · United States (5) · Australia (4) · Brazil (4) · Italy (4) · Poland (4) · United Kingdom (4) · Mexico (3) · Turkey (Türkiye) (3) · Argentina (2) · China (2) · Czechia (2)